NR3C1 and steatosis: GR antagonism with RU486 has favorable metabolic effects on body weight and fat mass, but is likely to cause side effects by inhibiting PR and AR transcriptional activity, while the use of CORT125281 may be limited due to adverse steatosis–inducing effects in mice.